Moreover, treatment with sunitinib, targeting multiple tyrosine kinases, significantly reduced UFMylation levels, while upregulation of active UFM1 was found to partially counteract the anti-tumor effects of sunitinib. This evidence concerns the gene UFM1 and neoplasm.